We reinvent, reposition, and reformulate drugs.

We believe that improving the world begins with improving the health of its citizens.

Learn More

iCo Therapeutics Overview

iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Management strength is supported by an impressive group of Directors and Advisors.

There is a significant decrease in development risk associated with targeting existing drugs, including:

  1. Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
  2. Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
  3. The target and mechanism of action has been identified.

Explore the Current Assets That We Are Currently Focused On


Our Current Assets

The Unique iCo Advantage



 we focus efforts on development instead of research
 we want measurable improvements in the lives of our patients
 we value long term thinking, deep commitment, and fiscal prudence

LEARN MORE

iCo Investment Information

See the latest investor updates, news releases, and review recent presentations and the upcoming Events where iCo will be featured and discussed.